While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo Nordisk's ...

London stocks nudged higher in early trade on Wednesday as investors mulled disappointing US tech results and continued to ...

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...

Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

European stocks remained flat in early trading Wednesday, as gains in healthcare were counterbalanced by a decline in ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

Wall Street was mostly lower on Wednesday despite US employment growth picking up last month by more than expected.